RedMabs in vivo antibody discovery platform is a disruptive tool in the immunization field. A combination of antigen design, immunization protocols, and BioClonal own adjuvants and immunomodulators originates this novel platform. Application of this platform fundamentally gives rise to two phenomena: An expansion of the germ line and the directionality of immunodominance. As a consequence, a greater number of antigen-specific B cells can be obtained, as well as a greater percentage of these towards the desired epitope. Of special interest is the use of this platform in immunogens against which antibodies cannot be obtained with common protocols. This would be the case, for example, of very small antigens such as carbohydrates or low molecular weight proteins, poorly immunogenic epitopic areas, or immunogens whose receptor ligand system is unknown.
A combination of antigen design, immunization protocols, and BioClonal own adjuvants and immunomodulators originates this novel platform.
Hybridoma technology had been used in the last century to obtain important drugs for several diseases, improving patients prognosis. However, it is known that efficiency of positiveness in this method is not high. It is established around 10-20% of success in common immunization protocols. Last advantages in high throughput screening or single B cells technologies increased this percentages by factor 4 to 5 the efficiency of common ELISA protocols. However, if total success in terms of positiveness against native targets is fixed, single B cell technologies wont unfold their full potential. RedMabs platforms showed a clear increased in the efficiency of positiveness against native protein in this case, even though common screening method were used.
Combination of RedMabs platform and single B cell technologies would be an enormous advantage in the antibody discovery in the near future.